RT Journal Article
SR Electronic
T1 Genetic landscape of rare autoinflammatory disease variants in Qatar and Middle Eastern populations through the integration of genomic datasets
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.10.20171363
DO 10.1101/2020.08.10.20171363
A1 Parul Sharma
A1 Abhinav Jain
A1 Vinod Scaria
YR 2020
UL http://medrxiv.org/content/early/2020/08/12/2020.08.10.20171363.abstract
AB Rare autoinflammatory diseases are a group of recurrent inflammatory genetic disorders caused due to genetic mutations in over 37 genes and typically have a recessive mode of inheritance. While a number of these disorders have been identified and reported from the Middle Eastern populations, the carrier frequency of these genetic mutations in the Middle Eastern populations is not known. The availability of whole-genome and exome datasets of over a thousand individuals from Qatar persuaded us to explore the genetic epidemiology of rare autoinflammatory genetic variants in the Middle East. We have systematically analyzed genetic variants in genome-scale datasets from Qatar with a compendium of variants associated with autoinflammatory diseases. The variants were further systematically reclassified according to the American College of Medical Genetics and Genomics (ACMG & AMP) guidelines for interpretation of pathogenicity of sequence variants. Our analysis identified 7 pathogenic and likely pathogenic variants with a significant difference in their allele frequencies compared to the global population. The cumulative carrier frequency of these variants was 2.58%. Furthermore, our analysis revealed that 5 genes implicated in rare autoinflammatory diseases were under natural selection. To our best knowledge, this is the first and comprehensive study on the population-scale analysis and genetic epidemiology for genetic variants causing rare autoinflammatory disease in any Middle Eastern population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAuthors acknowledge funding from the Council of Scientific and Industrial Research (CSIR, India) through Grant MLP1809 (IndiGen). Abhinav Jain is a recipient of Senior Research Fellowship from Council of Scientific and Industrial Research (CSIR, India). We have not recieved any funding from third party.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We have downloaded the data from Sequence Read Archive, does not require any approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the NCBI Sequence Read Archive (SRA accessions SRP060765, SRP061943 and SRP061463, accessible online at http://www.ncbi.nlm.nih.gov/Traces/study/?acc=SRP060765%2CSRP061943%2CSRP061463&go=go. (SRA accession SRP061943).